NBL-028

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameNBL-028
Drug Alias NameAnti-CLDN6-CD137 BsAbNBL-028NBL028
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CLDN6Anti-Tumor necrosis factor receptor superfamily member 9T lymphocytes stimulants +[4] 
TargetsClaudin 6Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Xinshi Biological Medicine Co LtdNovarock Biotherapeutics Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNovarock Biotherapeutics LtdShanghai Xinshi Biological Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A